Interpace Biosciences Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 2/6
Interpace Biosciences has a total shareholder equity of $-12.5M and total debt of $6.8M, which brings its debt-to-equity ratio to -54.3%. Its total assets and total liabilities are $13.0M and $25.5M respectively. Interpace Biosciences's EBIT is $4.4M making its interest coverage ratio 5. It has cash and short-term investments of $2.0M.
Anahtar bilgiler
-54.3%
Borç/özkaynak oranı
US$6.78m
Borç
| Faiz karşılama oranı | 5x |
| Nakit | US$2.02m |
| Eşitlik | -US$12.49m |
| Toplam yükümlülükler | US$25.46m |
| Toplam varlıklar | US$12.97m |
Son finansal sağlık güncellemeleri
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: IDXG has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Uzun Vadeli Yükümlülükler: IDXG has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: IDXG has negative shareholder equity, which is a more serious situation than a high debt level.
Borcun Azaltılması: IDXG's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Borç Kapsamı: IDXG's debt is well covered by operating cash flow (52.9%).
Faiz Kapsamı: IDXG's interest payments on its debt are well covered by EBIT (5x coverage).